Recent News

• 08.25.2026 - AI Drug Discovery Leaders Gain a Competitive Edge with Telesis Bio’s Gibson SOLA® Platform, Generating Development Candidates Faster
• 10.23.2023 - From Challenges to Triumph: iGem Team’s Success Story with Telesis Bio and the BioXp® System
• 10.23.2023 - From Challenges to Triumph: iGem Team’s Success Story with Telesis Bio and the BioXp® System
• 06.09.2023 - How to Reduce Lead Synthesis Bottlenecks in Antibody Discovery
• 06.09.2023 - How to Reduce Lead Synthesis Bottlenecks in Antibody Discovery
• 03.02.2023 - In our DNA: Pavel Ryzhov, Field Application Scientist
• 03.02.2023 - In our DNA: Pavel Ryzhov, Field Application Scientist
• 02.22.2023 - Synthetic Biology: Broadening the Horizons of Antibody Discovery
• 02.22.2023 - Synthetic Biology: Broadening the Horizons of Antibody Discovery
• 01.31.2023 - Removing bottlenecks in discovery workflows with synthetic biology solutions

Recent Filings

• 01.14.2025 - 15-12G Securities registration termination [Section 12(g)]
• 01.06.2025 - EFFECT Notice of Effectiveness
• 01.06.2025 - EFFECT Notice of Effectiveness
• 01.03.2025 - POS AM Post-Effective amendments for registration statement
• 01.03.2025 - POS AM Post-Effective amendments for registration statement
• 01.03.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 01.03.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 01.03.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 01.03.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 11.08.2024 - 8-K Current report